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Mineralocorticoid Receptor Antagonists (MRA) have proven their cardio-
protective effects in individuals with chronic heart failure (CHF) by mini-
mizing the cardiovascular damages caused by the excessive aldosterone
production observed in those patients. Metabolic syndrome (MetS) that repre-
sents one of the major risk factors for CHF has been also reported to be asso-
ciated with increased aldosterone levels and MR activation and may contribute
in that way to the pathogenesis of HF. Thus, we hypothesized that targeting
the MetS by the early antagonism of the MR may prevent or delay the subse-
quent transition to CHF in a rat model of HF associated or not with a MetS.
MRA Eplerenone (100 mg/kg/day) or placebo was administrated to
1.5 month-old obese and lean Spontaneously Hypertensive Heart Failure male
rats (SHHFcp/cp and SHHF+/+ respectively) for a period of 11 months. Animal
metabolic and cardiac parameters were regularly monitored during the pro-
tocol. When compared to the SHHF+/+, MetS rats induces of mortality of 30%
in SHHFcp/cp group that was completely prevented by the preventive treatment
with Eplerenone. Indeed, SHHFcp/cp developed over time a massive obesity,
dyslipidemia and insulin resistance. Echocardiograms showed an accelerated
transition to cardiac dysfunction evidenced by left ventricular hypertrophy
(LVH), a decreased relaxation and contractile properties of the myocardium as
well as LV dilatation. MRA, prevented rats’ body weight gain (–10%), dys-
lipidemia (–50%) and enhanced adiponectinemia (+50%). Independently of a
blood pressure decrease, cardiac parameters of Eple-SHHFcp/cp rats were pre-
served compared to SHHFcp/cp: LV diameter (9.9±0.14 vs 11.4±0.13 mm,
respectively), LV mass (1760±72 vs 2195±73 mg), ejection fraction (70±1 vs
59±1%), isovolumic relaxation time (30±1 vs 22±1 ms) and E/A ratio
(1.7±0.1 vs 3±0.3). Altogether, our data demonstrated that administration of
eplerenone at the very early stages of MetS delayed their progression to CHF
and prevented mortality. The beneficial cardioprotective effects were obtained
via a mechanism independent of blood pressure lowering.
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Background: Mesenchymal stem cells (MSCs) are widely used for cell
therapy, particularly for the treatment of ischemic heart disease. Mechanisms
underlying control of their proliferation capacity, which is known to be
inversely correlated to their differentiation abilities, have not been fully char-
acterized. The AMP-activated protein kinase (AMPK) controls several cell
functions including cell proliferation.
Objective: We hypothesized that AMPK plays a crucial role in the control
of MSC proliferation.
Methods: MSCs isolated from WT or AMPKα1 KO adult mouse bone
marrow were stimulated with the specific AMPK activator, A769662. Protein
phosphorylation state was determined by immunoblotting, cell viability was
quantified by FACS after AnnexinV and Propidium Iodide staining, cell pro-
liferation was quantified by EdU incorporation and gene expression was ana-
lyzed by real-time PCR.
Results: MSCs isolated from murine bone marrow exclusively expressed
the AMPKa1 catalytic subunit. A769662 was able to induce a robust and sus-
tained AMPK activation in WT MSCs but not in AMPKa1 KO MSCs. This
A769662-dependent AMPK activation blocks WT MSC proliferation but not
in KO MSCs without affecting their viability. Moreover, AMPKa1 deletion
induces an increase of basal MSC proliferation. Among AMPK downstream
targets proposed to regulate cell proliferation, we showed that neither the p70
ribosomal S6 protein kinase/eukaryotic elongation factor 2-dependent protein
synthesis pathway nor p21 was involved, whereas p27 expression was
increased by A-769662. Silencing p27 expression prevented the A-769662-
dependent inhibition of MSC proliferation.
Conclusions: These results suggest that activating AMPK promotes a prin-
cipal prerequisite for cell differentiation, the arrest of MSC proliferation via
p27 regulation.
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Cardiac failure is the most common cause of mortality in Friedreich ataxia
(FRDA), a mitochondrial disease with neurodegeneration, hypertrophic car-
diomyopathy and diabetes. FRDA is caused by reduced levels of frataxin
(FXN), an essential mitochondrial protein involved in mitochondrial bioener-
getics. To date, no treatment exists for FRDA cardiomyopathy. Here, we show
that adenoassociated virus (AAV) rh10 vector expressing human FXN injected
intravenously not only prevented the onset of the cardiac disease in a faithful
FRDA cardiac mouse model, but also, when administered at the time of heart
failure, reversed rapidly and completely cardiac disease at the functional, cel-
lular and molecular level in all treated animals. Our results also demonstrate
the capacity of defective cardiomyocytes with severe energy failure and ultra-
structure disorganization to be rapidly corrected and remodeled by gene
therapy. These results establish the primary proof-of-concept for developing
gene therapy of FRDA cardiomyopathy.
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